(Q29614972)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

30 April 2017

1 reference

Karran E

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

30 April 2017

Mercken M

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

30 April 2017

De Strooper B

series ordinal

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

19 August 2011

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

Nature Reviews Drug Discovery

30 April 2017

published in

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

30 April 2017

volume

10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

30 April 2017

page(s)

698-712

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

30 April 2017

issue

9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

Targeting Abeta and tau in Alzheimer's disease, an early interim report

30 April 2017

cites work

1 reference

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

31 March 2020

1 reference

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

31 March 2020

1 reference

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

31 March 2020

1 reference

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

31 March 2020

1 reference

Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

31 March 2020

1 reference

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein

31 March 2020

1 reference

Purification and cloning of amyloid precursor protein beta-secretase from human brain

31 March 2020

1 reference

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

31 March 2020

1 reference

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

31 March 2020

1 reference

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

31 March 2020

1 reference

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

31 March 2020

1 reference

Alzheimer's disease: the amyloid cascade hypothesis

31 March 2020

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

31 March 2020

1 reference

The molecular pathology of Alzheimer's disease

31 March 2020

1 reference

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

31 March 2020

1 reference

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

31 March 2020

1 reference

Candidate gene for the chromosome 1 familial Alzheimer's disease locus

31 March 2020

1 reference

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

31 March 2020

1 reference

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

31 March 2020

1 reference

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

31 March 2020

1 reference

Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene

31 March 2020

1 reference

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

31 March 2020

1 reference

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease

31 March 2020

1 reference

The role of apolipoprotein E in Alzheimer's disease

31 March 2020

1 reference

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

31 March 2020

1 reference

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

31 March 2020

1 reference

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

31 March 2020

1 reference

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

31 March 2020

1 reference

Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.

31 March 2020

1 reference

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

31 March 2020

1 reference

Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains.

31 March 2020

1 reference

The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease

31 March 2020

1 reference

Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain

31 March 2020

1 reference

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

31 March 2020

1 reference

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

31 March 2020

1 reference

Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease.

31 March 2020

1 reference

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

31 March 2020

1 reference

Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition

31 March 2020

1 reference

beta-Amyloid degradation and Alzheimer's disease

31 March 2020

1 reference

Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations.

31 March 2020

1 reference

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

31 March 2020

1 reference

In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life

31 March 2020

1 reference

The choroid plexus-cerebrospinal fluid system: from development to aging.

31 March 2020

1 reference

Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism

31 March 2020

1 reference

Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide

31 March 2020

1 reference

Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice

31 March 2020

1 reference

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

31 March 2020

1 reference

Long-term in vivo imaging of β-amyloid plaque appearance and growth in a mouse model of cerebral β-amyloidosis.

31 March 2020

1 reference

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

31 March 2020

1 reference

Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition

31 March 2020

1 reference

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

31 March 2020

1 reference

Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice

31 March 2020

1 reference

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

31 March 2020

1 reference

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

31 March 2020

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

31 March 2020

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

31 March 2020

1 reference

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

31 March 2020

1 reference

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease

31 March 2020

1 reference

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

31 March 2020

1 reference

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

31 March 2020

1 reference

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

31 March 2020

1 reference

Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain.

31 March 2020

1 reference

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

31 March 2020

1 reference

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

31 March 2020

1 reference

Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process

31 March 2020

1 reference

Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo

31 March 2020

1 reference

Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency

31 March 2020

1 reference

Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing.

31 March 2020

1 reference

Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations

31 March 2020

1 reference

Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms

31 March 2020

1 reference

Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease

31 March 2020

1 reference

When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease

31 March 2020

1 reference

DAPT-induced intracellular accumulations of longer amyloid beta-proteins: further implications for the mechanism of intramembrane cleavage by gamma-secretase.

31 March 2020

1 reference

gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment.

31 March 2020

1 reference

Potent amyloidogenicity and pathogenicity of Aβ43.

31 March 2020

1 reference

Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease

31 March 2020

1 reference

Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life

31 March 2020

1 reference

Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease

31 March 2020

1 reference

Abeta40 inhibits amyloid deposition in vivo.

31 March 2020

1 reference

Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host

31 March 2020

1 reference

Neuropathological stageing of Alzheimer-related changes

31 March 2020

1 reference

Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease.

31 March 2020

1 reference

Age, neuropathology, and dementia.

31 March 2020

1 reference

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

31 March 2020

1 reference

Transmission and spreading of tauopathy in transgenic mouse brain

31 March 2020

1 reference

Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions

31 March 2020

1 reference

Stopping a thief and killer: Alzheimer's disease crisis demands greater commitment to research.

31 March 2020

1 reference

Survival in Alzheimer disease: a multiethnic, population-based study of incident cases

31 March 2020

1 reference

Survival after Initial Diagnosis of Alzheimer Disease

31 March 2020

1 reference

Alzheimer Disease and Mortality

31 March 2020

1 reference

Genotype and phenotype in Alzheimer's disease

31 March 2020

1 reference

Rate of progression in familial Alzheimer's disease.

31 March 2020

1 reference

The clinical phenotype of familial and sporadic late onset Alzheimer's disease.

31 March 2020

1 reference

Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

31 March 2020

1 reference

Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.

31 March 2020

1 reference

The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort.

31 March 2020

1 reference

APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease.

31 March 2020

1 reference

Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease.

31 March 2020

1 reference

APOE genotype and survival in men and women with Alzheimer's disease.

31 March 2020

1 reference

The influence of ApoE4 on clinical progression of dementia: a meta-analysis

31 March 2020

1 reference

Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred.

31 March 2020

1 reference

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

31 March 2020

1 reference

Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration

31 March 2020

1 reference

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

31 March 2020

1 reference

A specific amyloid-beta protein assembly in the brain impairs memory

31 March 2020

1 reference

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

31 March 2020

1 reference

Solution state characterization of amyloid beta-derived diffusible ligands

31 March 2020

1 reference

Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease

31 March 2020

1 reference

The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism

31 March 2020

1 reference

Gamma-secretase gene mutations in familial acne inversa

31 March 2020

1 reference

PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa).

31 March 2020

1 reference

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

31 March 2020

1 reference

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

31 March 2020

1 reference

Alzheimer's disease: clinical trials and drug development

31 March 2020

1 reference

Dementia of the Alzheimer type

31 March 2020

1 reference

A new rating scale for Alzheimer's disease.

31 March 2020

1 reference

Current Alzheimer's disease clinical trials: methods and placebo outcomes

31 March 2020

1 reference

The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials

31 March 2020

1 reference

The Clinical Dementia Rating (CDR): current version and scoring rules

31 March 2020

1 reference

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

31 March 2020

1 reference

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

31 March 2020

1 reference

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease

31 March 2020

1 reference

Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro.

31 March 2020

1 reference

Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis

31 March 2020

1 reference

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

31 March 2020

1 reference

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

31 March 2020

1 reference

Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010.

31 March 2020

1 reference

Onset and rate of cognitive change before dementia diagnosis: findings from two Swedish population-based longitudinal studies.

31 March 2020

1 reference

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

31 March 2020

1 reference

Common mechanisms of amyloid oligomer pathogenesis in degenerative disease

31 March 2020

1 reference

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

31 March 2020

1 reference

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

31 March 2020

1 reference

Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease

31 March 2020

1 reference

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

31 March 2020

1 reference

Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease.

31 March 2020

1 reference

The cerebral beta-amyloid angiopathies: hereditary and sporadic

31 March 2020

1 reference

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

31 March 2020

1 reference

12 December 2020

Presenilins: members of the gamma-secretase quartets, but part-time soloists too.

1 reference

12 December 2020

Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme

1 reference

12 December 2020

Dementia: a systematic approach to identifying reversible causes.

1 reference

12 December 2020

Slowing the progression of Alzheimer disease: methodologic issues.

1 reference

12 December 2020

2011 Alzheimer's disease facts and figures

1 reference

12 December 2020

Alzheimer's disease: the challenge of the second century

1 reference

12 December 2020

Staging of Alzheimer-related cortical destruction

1 reference

12 December 2020

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

12 December 2020

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1223213

1009624842

0 references

Fatcat ID

release_3imnnalbljbrtfrpjadwqpd7vy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3imnnalbljbrtfrpjadwqpd7vy

24 November 2022

mapped directly with Wikidata item

1223213

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21852788

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017